$1.92 Billion is the total value of Camber Capital Management LP's 37 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 64.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PRGO | Sell | PERRIGO CO PLC | $100,558,000 | -10.3% | 1,208,200 | -0.4% | 5.24% | +6.3% |
| ENDP | Sell | ENDO INTL PLC | $64,266,000 | -24.8% | 3,902,000 | -8.0% | 3.35% | -10.9% |
| CSII | Sell | CARDIOVASCULAR SYSTEMS INC | $60,525,000 | -15.0% | 2,500,000 | -16.7% | 3.15% | +0.7% |
| UAM | Sell | UNIVERSAL AMERICAN CORPORATION | $48,506,000 | +7.9% | 4,875,000 | -17.0% | 2.53% | +27.8% |
| NVTA | Sell | INVITAE CORP | $19,041,000 | -11.0% | 2,398,123 | -1.8% | 0.99% | +5.4% |
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $6,035,000 | -67.2% | 4,250,000 | -59.5% | 0.31% | -61.1% |
| Exit | BIOLASE INCcall | $0 | – | -1,841,173 | -100.0% | 0.00% | – | |
| Exit | INNOCOLL AG | $0 | – | -1,059,139 | -100.0% | -0.27% | – | |
| PLX | Exit | PROTALIX BIO THERAPEUTICS, INC | $0 | – | -13,275,000 | -100.0% | -0.33% | – |
| Exit | BIOLASE INC | $0 | – | -5,332,394 | -100.0% | -0.41% | – | |
| PTCT | Exit | PTC THERAPEUTICS | $0 | – | -2,000,000 | -100.0% | -1.23% | – |
| VRX | Exit | VALEANT PHARMACEUTICALS INT (USA) | $0 | – | -1,271,500 | -100.0% | -1.37% | – |
| THC | Exit | TENET HEALTHCARE CORP THC | $0 | – | -2,500,000 | -100.0% | -2.49% | – |
| CYH | Exit | COMMUNITY HEALTH SYS INC NE COM | $0 | – | -5,000,000 | -100.0% | -2.54% | – |
| MDCO | Exit | MEDICINES COMPANY | $0 | – | -2,000,000 | -100.0% | -3.32% | – |
| TEVA | Exit | TEVA PHARMACEUTICAL INDUSTRIES LTD (ADR)call | $0 | – | -2,000,000 | -100.0% | -4.05% | – |
| SPY | Exit | SPDR S&P 500 ETF Trustput | $0 | – | -2,250,000 | -100.0% | -21.40% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2017-03-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.